Macrogenics, Inc. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Revenue From Collaborative Agreements at $87.2 million, 58% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
175
|
150
|
150
|
59
|
152
|
77
|
105
|
64
|
60
|
158
|
92
|
| Revenue From Collaborative Agreements |
—
|
87
-27.3%
share 58.3%
|
120
+292.6%
share 80.0%
|
31
-74.4%
share 52.0%
|
119
+88.5%
share 78.5%
|
63
-35.3%
share 81.7%
|
98
+57.6%
share 93.2%
|
62
+5.8%
share 96.6%
|
59
-62.3%
share 97.5%
|
156
share 98.6%
|
—
|
| Contract Manufacturing |
—
|
53
+303.1%
share 35.2%
|
13
+32.8%
share 8.7%
|
10
-29.7%
share 16.7%
|
14
share 9.2%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Product |
—
|
—
|
16
-8.4%
share 11.0%
|
18
+7.2%
share 30.5%
|
17
+35.5%
share 11.0%
|
12
share 15.9%
|
—
|
—
|
—
|
—
|
—
|
| Revenue From Royality Agreements Member |
—
|
10
+1626.6%
share 6.5%
|
1
+30.2%
share 0.4%
|
0
share 0.7%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Revenue From Government Agreements |
—
|
—
|
2
+4.3%
share 1.1%
|
2
-19.1%
share 2.6%
|
2
+6.6%
share 1.3%
|
2
-74.7%
share 2.3%
|
7
+229.0%
share 6.8%
|
2
+46.5%
share 3.4%
|
1
-33.6%
share 2.5%
|
2
share 1.4%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MGNX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1125345
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.